Company intelligence / Profile preview

Citius Pharmaceuticals, Inc.

Cranford, New Jersey, United States

Ownership: Public · CTXR
Development stage: Commercial

Overview

FDA approved LYMPHIR for CTCL in August 2024; Mino-Lok completed Phase 3 trial in 2023 meeting primary and secondary endpoints; Halo-Lido completed Phase 2b trial in 2023; actively engaged with FDA for next steps on both programs

Therapeutic areas: GastroenterologyOncologyPulmonologyInfectious Diseases
Modalities: Targeted immunotherapyantibiotic solutionstopical formulationsstem cell therapy
Industry: Biotech

Drug pipeline

8 assets

denileukin diftitox

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

University of Texas MD Anderson Cancer CenterUniversity of Pittsburgh Medical Center

Financials

Market cap: $6.5M
Total revenue: $1.5M
Enterprise value: $-3.3M

Beyond the preview

Go deeper on Citius Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Citius Pharmaceuticals, Inc..

Explore the full profile